Metabolic Biomarkers in Thoracic Cancers Study
This study is looking at new ways to use magnetic resonance imaging (MRI) to examine lung tumors and other cancers in the chest area. Researchers want to see how these tumors use sugar for growth. They will use a special sugar solution called 13C-glucose and then study a small sample of the tumor after it's removed during surgery. The goal is to find better ways to detect cancer and help doctors decide on the best treatment plan. You might be able to join if you are over 18, need surgery for a suspected cancer in your chest, and do not have poorly controlled diabetes. The study aims to enroll 200 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study planning to enroll 200 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would undergo an MRI scan using 13C-glucose within 5 days of your scheduled surgery. A small sample of your tumor will be studied after surgery.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your DCE-MRI will be measured at one time, within 5 days of your scheduled surgery.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Metabolic Biomarkers in Thoracic Cancers
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Kemp H Kernstine, MD · PRINCIPAL_INVESTIGATOR · University of Texas Southwestern Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- DCE-MRIOne time - within 5 days of the scheduled surgery
Physicians and researchers will review the results of the imaging to determine if the patient will receive the \[U-13C\] glucose infusion.